Skip to content

David Leahy

  • Professor
  • CEO
  • Molplex
  • 30PublicationsNumber of items in David's My Publications folder on Mendeley.
  • 3Followers

Research interests

agentsalifemulti-property optimisationcloud computingsemantic webQSARcheminformaticsdrug discovery

About

David Leahy has over 25 years experience in drug discovery and development working as scientist, manager and entrepreneur in innovative new technology, strategic change, and business start-up. He spent 15 years in Research with what is now AstraZeneca, developing innovative technologies alongside active drug discovery projects. At ICI/Zeneca he managed a major component of the drug discovery operation while also leading global strategic change initiatives aimed at improving productivity, particularly in the pre-clinical phase. He left Zeneca to found Cyprotex PLC a unique, commercially successful and globally recognised company with a niche position in the provision of laboratory information on multiple drug properties. Cyprotex is now the world's largest ADME Tox CRO. He led the company through start-up, flotation on the London Stock Exchange and on to commercial success as CEO and CSO. From 2007-2010, he held positions at Newcastle University in the Medical Faculty and as a “Professor of Practice in the Business School. He is now CEO and co-founder of "Molplex -Drug Discovery on Demand as well as Chairman of Inkspot -- "Workflow in the Cloud" businesses

Followers (3)

Following (3)

Publications (5)

  • The panel of experts cloud pattern

    • Watson P
    • Hiden H
    • Woodman S
    • et al.
    N/AReaders
    N/ACitations
    Get full text
  • Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models

    • Leahy D
    N/AReaders
    N/ACitations
    Get full text
  • Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models.

    • Leahy D
    N/AReaders
    N/ACitations
    Get full text
  • Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54.

    • Coecke S
    • Ahr H
    • Blaauboer B
    • et al.
    N/AReaders
    N/ACitations
  • Prediction of in vivo tissue distribution from in vitro data. 2. Influence of albumin diffusion from tissue pieces during an in vitro incubation on estimated tissue-to-unbound plasma partition coefficients (Kpu)

    • Ballard P
    • Arundel P
    • Leahy D
    • et al.
    N/AReaders
    N/ACitations

Professional experience

CEO

Molplex

May 2008 - Present

Chairman

Inkspot

January 2008 - Present

Education history

PhD

School of Chemistry and Pharmacy, University of East Anglia

July 1983 - May 2012(29 years)

Salts Grammar School

July 1972 - May 2012(40 years)

BA

University of Cambridge, St John’s College

September 1972 - July 1976(4 years)